Skip to main content Accessibility help
  • Get access
    Check if you have access via personal or institutional login
  • Cited by 1
  • Print publication year: 2011
  • Online publication date: December 2011

57 - Management of spasticity

from Section IV - Therapy in clinical practice


Dalfampridine is a lipid-soluble small molecule that more readily crosses the blood-rain barrier and, therefore, its effects on the central nervous system (CNS) have been the subject of greater focus. The initial Phase 2 study determined the safety of escalating doses of dalfampridine in subjects with multiple sclerosis (MS), to explore a number of outcome measures, and examine dose related efficacy. A battery of assessments was performed weekly, including the MS Functional Composite (MSFC), fatigue questionnaires, lower extremity manual muscle testing, and spasticity assessment using the Ashworth scale. The results supported the idea that quantitative functional outcome measures (such as walking speed derived from timed gait and lower extremity muscle testing) were sufficiently sensitive to demonstrate efficacy. Based on evaluation, the US food and drug administration (FDA) approved the extended release (ER) formulation of dalfampridine (daily oral dose of 10 mg BID) for use in MS to improve walking.


1. Lance J. Symposium synopsis. In Feldman RG, Young RR, Koella WP, eds. Spasticity: Disordered Motor Control. Chicago: Year Book Medical Publishers, 1980;485–94.
2. Matthews B. Symptoms and signs of multiple sclerosis. In Compston A, Ebers G, Lassmann H, McDonald I, Matthews B, Wekerle H, eds. McAlpine's Multiple Sclerosis. London: Churchill Livingstone, 1998.
3. Rizzo M, Hadjimichael O, Preiningerova J, Vollmer T. Prevalence and treatment of spasticity reported by multiple sclerosis patients. Mult Scler 2004; 10:589–95.
4. Walther E, Hohlfeld R. Multiple sclerosis: side effects of interferon beta therapy and their management. Neurology 1999; 53:1622–7.
5. Young R. Spasticity: a review. Neurology 1994; 44:S12–20.
6. Herman R, Freedman W, Meeks S. Physiological aspects of hemiplegic and paraplegic spasticity. In Desmedt J, ed. New Developments in Electromyography and Clinical Neurophysiology. Basel: Karger, 1973.
7. Ashworth B. Preliminary trial of carisoprodol in multiple sclerosis. Practitioner 1964; 192:540–2.
8. Bohannon R, Smith M. Inter-rater reliability of a modified Ashworth scale of muscle spasticity. Phys Ther 1987; 67:206–7.
9. Ghotbi N, Ansari NN, Naghdi S, et al. Inter-rater reliability of the Modified Ashworth Scale in assessing lower limb muscle spasticity. Brain Injury 2009; 23:815–19.
10. Pandyan AD, Johnson GR, Price CIM, et al. A review of the properties and limitations of the Ashworth and Modified Ashworth Scales as measures of spasticity. Clin Rehab 1999; 13:373–83.
11. Fleuren JF, Voerman GE, Erren-Wolters CV, et al. Stop using the Ashworth Scale for the assessment of spasticity. J Neurol Neurosurg Psychiatry 2010; 81:46–52.
12. Tardieu G, Shentoub S, Delarue R. A la recherche d'une technique de mesure de la spasticite. Rev Neurol 1954; 91:143–4.
13. Love S, Valentine J, Blair E, et al. The effect of botulinum toxin type A on the functional ability of the child with spastic hemiplegia a randomized controlled trial. J Neurol 2001; 8(Suppl 5):50–8.
14. Bajd T, Vodovnik L. Pendulum testing of spasticity. J Biomed Eng 1984; 6:9–16.
15. Delwaide P. Human monosynaptic reflexes and presynaptic inhibition: an interpretation of spastic hyperreflexia. In Desmedt J, ed. New Developments in Electromyography and Clinical Neurophysiology. Basel: Karger, 1973.
16. Stokic D, Yablon S, Hayes A. Comparison of clinical and neurophysiologic responses to intrathecal baclofen bolus administration in moderate-to-severe spasticity after acquired brain injury. Arch Phys Med Rehab 2005; 86:1801–6.
17. Penn RD, Savoy SM, Corocs D, et al. Intrathecal baclofen for severe spinal spasticity. N Engl J Med 1989; 320:1517–21.
18. Farrar JT, Troxel AB, Stott C, Duncombe P, Jensen MP. Validity, reliability, and clinical importance of change in a 0–10 numeric rating scale measure of spasticity: a post hoc analysis of a randomized, double-blind, placebo-controlled trial. Clin Ther 2008; 30:974–85.
19. Anwar K, Barnes MP. A pilot study of a comparison between a patient scored numeric rating scale and clinician scored measures of spasticity in multiple sclerosis. Neurorehabilitation 2009; 24:333–40.
20. Hobart JC, Riazi A, Thompson AJ, et al. Getting the measure of spasticity in multiple sclerosis: the Multiple Sclerosis Spasticity Scale (MSSS-88). Brain 2006; 129:224–34.
21. Sosnoff J, Motl RW, Snook EM, Wynn D. Effect of a 4-week period of unloaded leg cycling exercise on spasticity in multiple sclerosis. Neurorehabilitation 2009; 24:327–31.
22. Multiple Sclerosis Council for Clinical Practice Guidelines. Spasticity management in multiple sclerosis. Consortium of Multiple Sclerosis Centers, 2003.
23. Giovannelli M, Borriello G, Castri P, Prosperini L, Pozzilli C. Early physiotherapy after injection of botulinum toxin increases the beneficial effects on spasticity in patients with multiple sclerosis. Clin Rehab 2007; 21:331–7.
24. Giesser, Beres-Jones J, Budovitch A, Herlihy E, Harkema S. Locomotor training using body weight support on a treadmill improves mobility in persons with multiple sclerosis: a pilot study. Mult Scler 2007; 13:224–31.
25. Sosnoff JJ, Motl RW. Effect of acute unloaded arm versus leg cycling exercise on the soleus H-reflex in adults with multiple sclerosis. Neurosci Lett 2010; 479:307–11.
26. Nilsagard Y, Denison E, Gunnarsson LG. Evaluation of a single session with cooling garment for persons with multiple sclerosis-a randomized trial. Disabil Rehab Assist Technol 2006; 1:225–33.
27. Schyns F, Paul L, Finlay K, Ferguson C, Noble E. Vibration therapy in multiple sclerosis: a pilot study exploring its effects on tone, muscle force, sensation and functional performance. Clin Rehab 2009; 23:771–81.
28. Shakespeare D, Young C, Boggild M. Anti-spasticity agents for multiple sclerosis. Cochrane Database Syst Rev 2000; 4(CD-ROM)
29. Pinto O, Polikar M, Debono G. Results of international clinical trials with Lioresal. Postgrad Med J 1972; 48:18–23.
30. Feldman R, Kelly-Hayes M, Conomy J, Foley J. Baclofen for spasticity in multiple sclerosis: double-blind crossover and three year study. Neurology 1978; 28:1094–8.
31. Brar S, Smith M, Nelson L, Franklin G, Cobble N. Evaluation of treatment protocols on minimal to moderate spasticity in multiple sclerosis. Arch Phys Med Rehab 1991; 72:186–9.
32. Orsnes G, Sorensen P, Larsen T, Ravnborg M. Effect of baclofen on gait in spastic MS patients. Acta Neurol Scand 2000; 101:244–8.
33. Lapierre Y, Bouchard S, Tansey C, et al. Treatment of spasticity with tizanidine in multiple sclerosis. Can J Neurol Sci 1987; 14:513–17.
34. Nance P, Sheremata W, Lynch S, et al. Relationship of the antispasticity effect of tizanidine to plasma concentration in patients with multiple sclerosis. Arch Neurol 1997; 54:731–6.
35. Smolenski C, Muff S, Smolenski-Kautz S. A double-blind comparative trial of a new muscle-relaxant, tizanidine (DS102–282), and baclofen in the treatment of chronic spasticity in multiple sclerosis. Curr Med Res Opin 1981; 7:374–83.
36. Stein R, Nordal H, Oftedal S, Slettebo M. The treatment of spasticity in multiple sclerosis: a double-blind clinical trial of a new anti-spasticity drug tizanidine compared with baclofen. Acta Neurol Scand 1987; 75:190–4.
37. Hoogstraten M, Van Der Ploeg R, Van Der Burg W, et al. Tizanidine versus baclofen in the treatment of multiple sclerosis patients. Acta Neurol Scand 1988; 77:224–30.
38. Bass B, Weinsheker B, Rice G. Tizanidine versus baclofen in the treatment of spasticity in patients with multiple sclerosis. J Neurol Sci 1988; 15:15–19.
39. The United Kingdom Tizanidine Study Group. A double-blind placebo-controlled trial of tizanidine in the treatment of spasticity caused by multiple sclerosis. Neurology 1994; 44:70–9.
40. Vakhapova V, Auriel E, Karni A. Nightly sublingual tizanidine HCl in multiple sclerosis: clinical efficacy and safety. Clin Neuropharmacol 2010; 33:151–4.
41. From A, Heltberg A. A double-blind trial with baclofen and diazepam in spasticity due to multiple sclerosis. Acta Neurol Scand 1975; 51:158–66.
42. Cendrowski W, Sobczyk W. Clonazepam, baclofen, and placebo in the treatment of spasticity. Eur Neurol 1977; 16:257–62.
43. Dunevsky A, Perel A. Gabapentin for relief of spasticity associated with multiple sclerosis. Am J Phys Med Rehab 1998; 77:451–4.
44. Cutter N, Scott D, Johnson J, Whiteneck G. Gabapentin effect of spasticity in multiple sclerosis: a placebo-controlled, randomized trial. Arch Phys Med Rehab 2000; 81:164–9.
45. Gelenberg A, Poskanzer D. The effect of dantrolene sodium on spasticity in multiple sclerosis. Neurology 1973; 23:1313–15.
46. Tolosa E, Soll R, Loewenson R. Treatment of spasticity in multiple sclerosis with dantrolene (letter). J Am Med Assoc 1975; 233:1046.
47. Donovan W, Carter R, Rossi C, Wilkerson M. Clonidine effect on spasticity: a clinical trial. Arch Phys Med Rehab 1988; 69:193–4.
48. Nance P, Shears A, Nance D. Clonidine in spinal cord injury. Can Med Assoc J 1985; 133:41–2.
49. Yablon S, Sipski M. Effect of transdermal clonidine on spinal spasticity: a case series. Am J Phys Med Rehabil 1993; 72:154–7.
50. Baker D, Pryce G, Croxford J, et al. Cannabinoids control spasticity and tremor in a multiple sclerosis model. Nature 2000; 404:84–7.
51. Petro D, Ellenberger C. Treatment of human spasticity with delta-9-tetrahydrocannabinol. J Clin Pharmacol 1981; 21:413S–16S.
52. Collin C, Ehler E, Waberzinek G, et al. A double-blind, randomized, placebo-controlled, parallel-group study of Sativex in subjects with symptoms of spasticity due to multiple sclerosis. Neurol Res 2010; 32:451–9.
53. Wade DT, Collin C, Stott C, Duncombe P. Meta-analysis of the efficacy and safety of Sativex (nabiximols) on spasticity in people with multiple sclerosis. Mult Scler 2010; 16:707–14.
54. Barbeau H, Richards C, Bedard B. Action of cyproheptadine in spastic paraparetic patients. J Neurol Neurosurg Psychiatry 1982; 45:923–6.
55. Gironi M, Martinelli-Boneschi F, Sacerdote P, et al. A pilot trial of low-dose naltrexone in primary progressive multiple sclerosis. Mult Scler 2008; 14:1076–83.
56. Brin M. Botulinum toxin: chemistry, pharmacology, toxicity, and immunology. Muscle Nerve 1997;Suppl 6:S146–68.
57. Simpson DM, Gracies JM, Graham HK, et al. Assessment: Botulinum neurotoxin for the treatment of spasticity (an evidence-based review): report of the Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology. Neurology 2008; 70:1691–8.
58. Snow B, Tsui J, Bhatt M, et al. Treatment of spasticity with botulinum toxin: a double-blind study. Ann Neurol 1990; 28:512–15.
59. Kerty E, Stein R. Treatment of spasticity with botulinum toxin. Tidsskr Nor Laegeforen 1997; 117:2022–4.
60. Borg-Stein J, Pine Z, Miller J, Brin M. Botulinum toxin for the treatment of spasticity in multiple sclerosis. Am J Phys Med Rehab 1993; 72:364–8.
61. Dalton CM, Keenan E, Jarrett L, Buckley L, Stevenson VL. The safety of baclofen in pregnancy: intrathecal therapy in multiple sclerosis. Mult Scler 2008; 14:571–2.
62. Abel N, Smith R. Intrathecal baclofen for treatment of intractable spinal spasticity. Arch Phys Med Rehab 1994; 75:54–8.
63. Azouvi P, Mane M, Thiebaut J, et al. Intrathecal baclofen administration for control of severe spinal spasticity: functional improvement and long-term follow-up. Arch Phys Med Rehab 1996; 77:35–9.
64. Becker W, Harris C, Long M, et al. Long term intrathecal baclofen therapy in patients with intractable spasticity. Can J Neurol Sci 1995; 22:208–17.
65. Nance P, Schryvers O, Schmidt B, et al. Intrathecal baclofen therapy for adults with spinal spasticity: therapeutic efficacy and effect on hospital admissions. Can J Neurol Sci 1995; 22:22–9.
66. Ordia J, Fischer E, Adamski E, Spatz E. Chronic intrathecal delivery of baclofen by a programmable pump for the treatment of severe spasticity. J Neurosurg 1996; 85:452–7.
67. Stempien L, Tsai T. Intrathecal baclofen pump use for spasticity. Am J Phys Med Rehab 2000; 79:536–41.
68. Jarrett L, Siobhan M, Porter B, et al. Managing spasticity in people with multiple sclerosis: a goal-oriented approach to intrathecal baclofen therapy. Int J MS Care 2001; 3:10–21.
69. Zahavi A, Geertzen JHB, Middel B, Staal M, Rietman JS. Long term effect (more than five years) of intrathecal baclofen on impairment, disability, and quality of life in patients with severe spasticity of spinal origin. J Neurol Neurosurg Psychiatry 2004; 75:1553–7.
70. Bensmail D, Quera Salva MA, Roche N, et al. Effect of intrathecal baclofen on sleep and respiratory function in patients with spasticity. Neurology 2006; 67:1432–6.
71. Auer C, Siebner H, Dressnandt J, Conrad B. Intrathecal baclofen increases corticospinal output to hand muscles in multiple sclerosis. Neurology 1999; 52:1298–9.
72. Sadiq SA, Wang GC. Long-term intrathecal baclofen therapy in ambulatory patients with spasticity. J Neurol 2006; 253:563–9.
73. Bethoux F, Gogol D, Schwetz K, Kinkel R. Use of a registry of intrathecal baclofen therapy in a large multiple sclerosis center: analysis of data on 82 patients and proposed changes (letter). Arch Phys Med Rehab 2001; 82:1329.
74. Bethoux F, Stough D, Sutliff M. Treatment of severe spasticity with intrathecal baclofen therapy in ambulatory multiple sclerosis patients: 6-month follow-up. Arch Phys Med Rehab 2004; 84:A10.
75. Delehanty L, Sadiq S. Use of combination intrathecal baclofen and morphine in MS patients with intractable pain and spasticity. Neurology 2001; 56:A99.
76. Masterson M, Sadiq S. Use of intrathecal clonidine infusion alone, or in combination with intrathecal baclofen, for relief of intractable pain syndromes. Neurology 2001; 56:A351.
77. Denys P, Chartier-Kastler E, Azouvi P, Remy-Neris O, Bussel B. Intrathecal clonidine for refractory detrusor hyperreflexia in spinal cord injured patients: a preliminary report. J Urol 1998; 160:2137–8.
78. Sindou M, Millet M, Mortamais J, Eyssette M. Results of selective posterior rhizotomy in the treatment of painful and spastic paraplegia secondary to multiple sclerosis. Appl Neurophysiol 1982; 45:335–40.